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ill T. Jesurum, PHD,* Cindy J. Fuller, PHD,* Joshua Renz, RVT,†
imberly A. Krabill, MD,* Merrill P. Spencer, MD,† Mark Reisman, MD*
eattle, Washington
bjectives We sought to assess the prevalence of secondary right-to-left circulatory shunt (RLS) in
atients undergoing transcatheter closure of patent foramen ovale (PFO) as detected by power M-
ode transcranial Doppler (TCD) and intracardiac echocardiography.
ackground Prevalence of residual RLS in late follow-up after PFO closure may be as high as 34%.
ther cardiac and noncardiac sources of RLS may coexist and obscure PFO closure evaluation.
ethods Eighty-eight patients who underwent transcatheter PFO closure to prevent recurrent para-
oxical cerebral embolism between June 2005 and December 2006 were evaluated for a secondary
ource of RLS. Before device deployment, a sizing balloon was inﬂated in the PFO tunnel and agi-
ated saline contrast was injected into the inferior vena cava. Clinically signiﬁcant secondary RLS was
eﬁned as 10 embolic tracks on TCD at rest or immediately after calibrated (40 mm Hg), sustained
10 s) respiratory strain, with corresponding negative color-ﬂow Doppler. Late residual RLS was eval-
ated in all patients with TCD and transthoracic echocardiography (mean: 192 days; 95% conﬁdence
nterval [CI]: 161 to 223 days).
esults The sample (n  84) was 59% female, age 49  14 years. Seventeen patients (20%; 95%
I: 11.7 to 28.8) had secondary RLS during balloon occlusion. At late follow-up (n  66), 13 of 14
93%) patients with secondary RLS and 23 of 52 (44%) patients without secondary RLS had residual
LS (p  0.002).
onclusions This is the ﬁrst report to systematically assess the prevalence of secondary RLS in pa-
ients undergoing PFO closure. Residual RLS detected by TCD may be due to secondary RLS, which
ay have implications for clinical outcomes. (J Am Coll Cardiol Intv 2009;2:561–7) © 2009 by the
merican College of Cardiology Foundation
rom the *Swedish Heart and Vascular Institute, Swedish Medical Center, and †Spencer Vascular, Inc., Seattle, Washington.
r. Merrill P. Spencer is now deceased.anuscript received September 29, 2008; revised manuscript received February 25, 2009, accepted April 20, 2009.
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562aradoxical cerebral embolism is presumed to be the leading
ause of cryptogenic ischemic stroke in patients with patent
oramen ovale (PFO) age 50 years. Approximately 70,000
trokes are attributed to PFO annually (1). The causal
echanism of stroke among persons with PFO is unclear,
ut may be related to the transient shunting of blood from
he right to left atrium across the PFO, thus permitting
mall thrombi or other substances of venous origin to bypass
ulmonary filtration and enter the systemic circulation (2).
See page 568
Transcatheter closure of PFO is associated with a low
ncidence of recurrent stroke. In an early meta-analysis (3),
he 1-year recurrence rate for neurological events was 0% to
.9% for PFO closure and 3.8% to 12.0% for medical
herapy. With improved closure devices and longer duration
f follow-up, the rate of recurrent stroke following PFO
losure ranges from 0% to 3.4% per year (4–6). In our
experience, the overall recurrent
stroke rate in patients who had
PFO closure for prevention of
recurrent stroke was 3.4% during
a mean follow-up of 568  364
days; for patients age 55 years,
the rate was 1.4% (7).
In recent reports, the rate of
residual right-to-left shunt
(RLS) following PFO closure
may be as high as 34% in late
follow-up (7,8). Residual RLS
has been associated with recur-
rent stroke following PFO clo-
sure (hazard ratio: 6.9, 95% con-
fidence interval [CI]: 1.3 to
6.9; p  0.03) (9). Cardiac and noncardiac sources of
irculatory shunt (e.g., pulmonary arteriovenous malforma-
ion [PAVM] or atrial septal defect [ASD]) may coexist
ith PFO and obscure the evaluation of residual RLS
ollowing transcatheter PFO closure; however, there are no
ublished population-based studies on the prevalence of
oexisting PAVM or ASD in patients with PFO.
The purpose of the present study was to obtain prelimi-
ary findings on the prevalence of secondary source of RLS
n patients with PFO at the time of transcatheter PFO
losure using a compliant sizing balloon, intracardiac echo-
ardiography (ICE), and power M-mode transcranial
oppler (TCD). We hypothesized that patients who had
ositive TCD during balloon occlusion of the PFO, sug-
estive of a noncardiac source of secondary RLS, would have
higher rate of residual RLS immediately following device
eployment and in late follow-up as compared with those who
bbreviations
nd Acronyms
SD  atrial septal defect
T  embolic track(s)
CE  intracardiac
chocardiography
AVM  pulmonary
rteriovenous malformation
FO  patent foramen ovale
LS  right-to-left shunt
CD  power M-mode
ranscranial Doppler
TE  transthoracic
chocardiographyad negative TCD during PFO balloon occlusion. dethods
his single-center, prospective study was approved by the
wedish Medical Center Institutional Review Board and
as performed in accordance with the ethical standards of
he 1964 Declaration of Helsinki. The target population
ncluded patients who underwent transcatheter PFO closure
t Swedish Medical Center between June 2005 and Decem-
er 2006. A consecutive, nonrandom technique was used to
elect the sample. Eligibility criteria for transcatheter PFO
losure included a presumed paradoxical embolic event;
vidence that RLS could be provoked, confirmed by TCD
nd transthoracic echocardiography (TTE) or transesopha-
eal echocardiography; and probe patency of the septal
unnel during catheterization.
Detection of embolic tracks (ET) was performed using
he PMD100 transcranial Doppler platform (Spencer Tech-
ologies, Seattle, Washington) in the Swedish Medical
enter Cardiac Catheterization Laboratory. A PMD100
-MHz ultrasound probe was mounted and stabilized over
ach temporal bone using the Marc 600 head frame (Spen-
er Technologies). Patients were placed in a supine position
ith the head raised 30° and measures were taken to avoid
eck rotation or flexion. After obtaining adequate bilateral
emporal bone window signals, all patients had at least 2
ontrast injections during TCD evaluation using methods
escribed by Spencer et al. (10). Each contrast injection
onsisted of 9 ml normal saline, 1 ml air, and a small
mount of the patient’s blood manually agitated between 2
yringes for 10 s and injected into the inferior vena cava in
he cardiac catheterization laboratory or in an antecubital
ein for follow-up evaluation (10,11). The first injection was
erformed during normal respiration (rest). The second
njection was performed immediately before performance of
alibrated respiratory strain. Each patient was instructed to
low into a mouthpiece attached to a manometer until 40
m Hg pressure was achieved and maintained for 10 s.
mbolic tracks for both injections were counted for 1 min
fter the microbubbles reached the pulmonary artery (10).
Intracardiac echocardiography was performed during
FO closure (Acuson AcuNav, Siemens, San Diego, Cali-
ornia) to evaluate PFO tunnel length, balloon-stretch
iameter, and the presence of coexisting atrial septal aneu-
ysm and/or ASD (12). A compliant, conforming sizing
alloon was used to assess PFO diameter and to guide
evice size selection. Balloon inflation was completed when
he PFO tunnel was completely occluded and a small waist
as visible on ICE. The inflated balloon waist diameter was
easured with the aid of calibrations on the sizing balloon.
eptal tunnel length was measured as the distance between
ight and left atria. Atrial septal characteristics were evalu-
ted post-procedurally by a single cardiologist (K.A.K.) with
xpertise in echocardiography. Atrial septal aneurysm was
efined as a localized protrusion of the fossa ovalis, with a
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563ase width 15 mm and mobile septal excursion into the
eft or right atrium 10 mm (13). Atrial septal defect was
efined as a predominant left-to-right shunt at rest, based
n color-flow Doppler interrogation. Patients who were
iagnosed with coexisting ASD were excluded from the
nalysis. After the procedure, antiplatelet therapy consisted
f clopidogrel 75 mg for 3 months and aspirin 325 mg for
6 months.
To evaluate the presence of secondary RLS, a novel
rocedure not previously described was employed. During
FO balloon inflation, color-flow Doppler in conjunction
ith ICE was used to confirm complete occlusion of the
FO tunnel, at rest and during respiratory strain. If color-
ow Doppler showed continual RLS during PFO balloon
nflation, the balloon was repositioned and/or reinflated to
cclude the tunnel. If color-flow Doppler confirmed the
bsence of RLS during balloon inflation, 10 ml of agitated
aline contrast was injected during normal respiration and
mmediately (5 s) prior to respiratory strain. Complete
alloon occlusion was achieved in all patients. No patients
ere excluded due to positive color-flow Doppler during
alloon occlusion. Right-to-left shunt was considered
ositive if ET were detected at either rest or following
espiratory strain. A clinically significant secondary RLS
as defined as 10 ET at rest or following respiratory
train during balloon occlusion of the PFO; 10 ET
onstituted the absence of a clinically significant second-
ry RLS. Although quantitation of ET ranged from 0 to
01, 301 indicating microemboli too numerous to count
10), a conservative periprocedural definition of second-
ry RLS was adopted for the study to avoid false positive
ndings.
Patients were divided into 2 groups, based on the pres-
nce or absence of secondary RLS during PFO balloon
cclusion. The TCD evaluation was performed at 3 separate
ime points (10 cc agitated saline injection at rest and
ollowing respiratory strain), reported in this analysis as: 1)
uring balloon occlusion of the PFO to assess for presence
f secondary RLS; 2) immediately following septal occluder
evice deployment to assess device placement and presence
f residual RLS; and 3) in late follow-up to determine
resence of residual RLS after closure. In late follow-up,
TE was used in conjunction with TCD to rule out a
ardiac source of residual RLS. For the purpose of this
tudy, size of residual RLS in late follow-up was based on
he number of ET during TCD following respiratory strain
nd arbitrarily classified as small (1 to 10 ET), moderate (11
o 100 ET), and large (100 ET).
tatistical analysis. Descriptive statistics were performed for
emographic and echocardiographic characteristics, dura-
ion of follow-up, recurrent events, and RLS. Data are
resented as mean  SD, mean and 95% CI for continuous
ata, or n (%) for categorical data. Comparisons between
roups with and without secondary RLS were performed for 1emographic, comorbidity, and TCD data by chi-square or
isher exact test for categorical data; continuous data were
ompared using independent sample t tests or Mann-
hitney U tests. Levene test was used to assess equality of
ariances for parametric tests. Linear regression analysis was
erformed to assess predictors of residual RLS at late
ollow-up. Assumptions of normality, linearity, and equality
f variances were assessed by examining histograms and
catter plots of predicted and residual values. Post hoc power
nalysis for the primary hypothesis was performed using
oncentral chi-square analysis. All statistical analyses were
erformed using SPSS version 15.0 and SamplePower
ersion 2.0 (SPSS Inc., Chicago, Illinois). The threshold
or statistical significance for all tests was set at alpha 
.05, 2-tailed.
esults
atient characteristics. Eighty-eight of 140 (63%) consecu-
ive patients were referred to the Swedish Medical Center
ardiac Catheterization Laboratory and underwent PFO
losure between June 2005 and December 2006 and were
valuated for secondary source of RLS. All patients under-
ent PFO closure to prevent recurrent cerebrovascular
vents due to presumed paradoxical embolism. Four patients
5%) were excluded from the analysis due to coexisting
SD; therefore, 84 patients were included in the final
ample. Four additional patients (5%) did not have TCD
valuation immediately following device deployment, which
epresented a protocol deviation. Eighteen patients (21%)
ere lost to follow-up and did not have TCD/TTE evalu-
tion after closure. Therefore, analysis in late follow-up was
ased on n  66.
During balloon occlusion of the PFO (n  84), 17 (20%;
5% CI: 11.7 to 28.8) patients had a positive TCD (ET: 11
o 301) with simultaneous negative color-flow Doppler,
uggestive of a clinically significant noncardiac source of
econdary RLS. Of the 18 lost to follow-up, 3 (17%) had a
econdary source of RLS. The demographic and procedural
haracteristics of groups with and without significant sec-
ndary RLS are listed in Table 1. The overall sample was
8% female and 83% Caucasian, age 49  14 years. The 18
atients lost to follow-up were 44% female, 89% Caucasian,
nd age 53 14 years. There were no differences in baseline
haracteristics for patients with and without follow-up.
eriprocedurally, patients with PFO and secondary RLS
ad a greater number of ET at rest and following respiratory
train than patients without secondary RLS, although the
ifferences were not statistically or clinically significant (p
.3 and p  0.1, respectively). Furthermore, patients with
econdary RLS had a higher prevalence of atrial septal
neurysm than patients without secondary RLS did, al-
hough this also was not statistically significant (24% vs.
8%, respectively; p  0.7). On average, patients with
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564econdary RLS had larger PFO waist diameters than those
ithout secondary RLS (14  4 mm vs. 11  3 mm,
espectively; p  0.013); however, the prevalence of comor-
id conditions and other septal characteristics were similar
etween the groups with and without secondary RLS
Transcranial Doppler assessment of RLS was performed
mmediately after septal occluder device deployment in 80
95%) patients; due to protocol deviation, 4 patients did not
eceive TCD evaluation following device deployment, none
f whom had secondary RLS. Patients who had secondary
LS had a higher proportion of residual RLS (ET: 1 to
01) immediately following device deployment than those
ho did not have secondary RLS (94% vs. 56%, respec-
ively; p  0.004) (Fig. 1).
During TCD evaluation at late follow-up (mean: 192
ays, 95% CI: 161 to 223 days; n  66), 36 (55%) patients
n the sample had residual RLS (1 to 301 ET). In compar-
ng groups with and without secondary RLS, 13 of 14 (93%)
atients who had secondary RLS during PFO balloon
cclusion had residual RLS at late follow-up. In contrast,
he remaining 23 of 52 (44%) patients without secondary
LS during balloon occlusion had a much lower prevalence
f residual RLS at late follow-up (93% vs. 44%; p  0.002)
Fig. 2). The difference between the number of ET at rest
Table 1. Demographic and Procedural Characteristic
Balloon Occlusion (n  84)
Characteristic
Patients
Age, yrs
Females
Caucasian
Number of strokes before PFO closure
Number of transient ischemic attacks
before PFO closure
Migraine history
Coexisting atrial septal aneurysm
Embolic tracks on TCD at rest, pre-closure
Embolic tracks on TCD after calibrated
respiratory strain, pre-closure
PFO balloon diameter, mm
PFO tunnel length, mm
Device*
CardioSEAL
Amplatzer
Helex
Device size, mm
23
28
33
Other
*CardioSEAL (NMT Medical, Boston, Massachusetts); Amplatzer (AGA M
PFO patent foramen ovale; RLS right-to-left shunt; TCD pows of Groups With and Without Secondary RLS Following
With Secondary RLS
(n  17)
Patients Without Secondary RLS
(n  67)
46 13 49 14
10 (59%) 39 (58%)
16 (94%) 54 (81%)
1.3 0.6 1.2 0.5
1.4 0.5 1.6 0.6
7 (41%) 26 (41%)
4 (25%) 12 (18%)
148 139 116 117
269 73 235 108
13.9 4.3 11.4 3.4 (p 0.013)
12.3 2.6 11.0 3.0
15 (88%) 61 (87%)
1 (6%) 6 (9%)
1 (6%) 0
4 (24%) 25 (37%)
5 (29%) 28 (42%)
5 (29%) 6 (9%)
3 (18%) 8 (12%)
edical, Golden Valley, Minnesota); Helex (W.L. Gore, Flagstaff, Arizona).nd following respiratory strain was higher in the groupFigure 1. Prevalence of Residual RLS Immediately Following PFO Device
Deployment
Patients were grouped based on presence or absence of secondary RLS
during balloon occlusion of PFO. Secondary RLS was deﬁned as 10
embolic tracks, at rest or after respiratory strain, as measured by power
M-mode transcranial Doppler during balloon occlusion of PFO. *94% versus
56%, p  0.004 between patients with and without secondary RLS. PFO 
patent foramen ovale; RLS  right-to-left shunt.
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565ith secondary RLS (105  131; p  0.01) than in the
roup without secondary RLS (43  85; p  0.001) in late
ollow-up. For the observed effect size (0.49; 95% CI: 0.030
o 0.68) of secondary RLS on late residual RLS, and sample
izes of 14 and 52 for the 2 groups, the study had 97% power
o detect a statistically significant difference (alpha  0.05,
-tailed).
Overall, 30% (20 of 66) of patients in the sample had
arge residual RLS (101 to 301 ET) at late follow-up. In
omparing groups, 71% (10 of 14) of patients with second-
ry RLS during PFO balloon occlusion had large residual
LS versus 19% (10 of 52) of patients without secondary
LS (p  0.0001) (Fig. 3). Regression analysis revealed
hat: 1) PFO balloon waist diameter; and 2) the number of
T detected on TCD during balloon occlusion of PFO
either at rest or following respiratory strain) were predictive
f residual RLS following transcatheter PFO closure (bal-
oon waist: beta  0.34, p  0.002; ET during balloon
cclusion: beta  0.43, p  0.001).
iscussion
he primary objective of this study was to gather prelimi-
ary data on the prevalence of secondary RLS in patients
ndergoing transcatheter PFO closure for prevention of
ecurrent cerebrovascular events. Twenty percent (95% CI:
Figure 2. Prevalence of Residual RLS Following Transcatheter PFO
Closure in Late Follow-Up (198  126 Days; 95% Confidence Interval:
161 to 223)
Patients were grouped based on presence or absence of secondary RLS
during balloon occlusion of PFO. Secondary RLS was deﬁned as 10
embolic tracks after respiratory strain as measured by power M-mode
transcranial Doppler during balloon occlusion of PFO. *93% versus 44%, p
 0.002 between patients with and without secondary RLS. Abbreviations
as in Figure 1.1.7 to 28.8) of patients referred for PFO closure had aecondary source of RLS during balloon occlusion before
evice implantation as diagnosed by contrast-enhanced
CD and ICE. To our knowledge, this is the first study to
ystematically evaluate the prevalence of secondary source of
LS periprocedurally in patients with PFO. The combina-
ion of balloon occlusion of the PFO tunnel, ICE, and
CD allowed us to indirectly assess noncardiac sources of
LS before septal occluder device deployment. The com-
ination of TCD and ICE allowed optimal detection of
LS without the sedation required for transesophageal
chocardiography (14), which can limit a patient’s ability to
dequately perform respiratory strain (15) and may result in
false negative result. The use of ICE with color-flow
oppler allowed for direct visualization of the atrial septum
o rule out coexisting ASD and inadequate balloon occlu-
ion of the PFO.
Although the association between PFO and cryptogenic
troke remains controversial, the goal of PFO closure is to
educe or eliminate the risk of recurrent paradoxical embo-
ism by eliminating RLS. Late residual RLS is an indepen-
ent risk factor of recurrent stroke following PFO closure
9). Depending on the modality used to detect RLS, the
revalence of late residual RLS can be as high as 34%
ollowing transcatheter PFO closure (7,8). To adequately
valuate the “technical” success of PFO closure, it is impor-
ant to identify other noncardiac secondary sources of RLS
efore device implantation.
Figure 3. Size of Residual RLS, as Assessed by ET With TCD, in Late
Follow-Up After Transcatheter PFO Closure (192  126 Days;
95% Confidence Interval: 161 to 223)
The size of late residual RLS was signiﬁcantly different between patients
who had secondary RLS during balloon occlusion of PFO (p  0.003). The
proportion of large residual RLS was signiﬁcantly greater in patients who
had secondary RLS during balloon occlusion. *71% versus 19%, p  0.0001
for the presence of large residual RLS between patients with and without
secondary RLS. ET  embolic tracks; TCD  power M-mode transcranial Dopp-
ler; other abbreviations as in Figure 1.
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566The results of this study suggest that a secondary source
f RLS may contribute to the high prevalence of late
esidual RLS after transcatheter PFO closure. Patients who
ad secondary RLS during balloon occlusion of PFO had a
ignificantly higher rate of residual RLS immediately fol-
owing PFO device deployment compared with those with-
ut secondary RLS (94% vs. 56%). More importantly, these
ifferences persisted at late follow-up (93% and 44%). The
nding that 44% of patients in the present study who did
ot have secondary RLS had late residual RLS following
FO closure is consistent with our previously published
ndings of 34% residual RLS at 568  364 days after PFO
losure (7). The secondary source of RLS was not assessed
n this cohort.
In follow-up, concurrent TCD and TTE evaluation was
sed to diagnose residual RLS and distinguish between
ardiac and noncardiac sources of RLS. The TCD modality
sed in this study is more sensitive than transesophageal
chocardiography to detect RLS when compared with
natomical findings in the catheterization laboratory (98%
s. 91%) (10). Use of TCD may partially explain our
elatively high overall rate (55%) of residual RLS at late
ollow-up of 192 days (95% CI: 161 to 223 days). The high
ate of residual RLS may be device-specific, as nearly 90% of
ll patients were implanted with CardioSEALs (NMT
edical, Boston, Massachusetts).
The study was adequately powered to detect statistically
nd clinically significant differences in late residual RLS
etween the groups with and without a secondary source of
LS. In late follow-up, 30% (20 of 66) of patients in the
ample had large residual RLS (101 to 301 ET); 71% (10 of
4) of patients with secondary RLS during PFO balloon
cclusion versus 19% (10 of 52) of patients without second-
ry RLS (p  0.001). This is an important finding that
einforces the need to assess the presence of secondary
ource of RLS before transcatheter PFO closure.
The association between PFO balloon diameter and residual
LS is of concern. The morphology of PFO ranges from the
simple” to the large incompetent “valve” with or without an
trial septal aneurysm. Whether these larger openings repre-
ent a single developmental abnormality or are part of a
onstellation of abnormalities during embryogenesis should be
onsidered in future studies based on the present data. In
npublished data, our group has previously found nonsignifi-
ant correlations between balloon diameter of PFO and pre-
losure size of RLS as measured by TCD and ET quantifica-
ion at rest or following respiratory strain (n 84; r 0.09 and
 0.16, respectively, both p values 0.05).
Pulmonary arteriovenous malformation is the most likely
ause of secondary RLS not detectable by ICE, although
his was not confirmed with pulmonary angiography. Non-
ardiac sources of RLS such as PAVM have been associated
ith cerebrovascular events (16,17), and the presence of
ultiple PAVMs significantly increases the risk of cerebro- sascular events (odds ratio: 4.5; 95% CI: 1.47 to 14) (18).
ublished case reports have documented the coexistence of
oncardiac source of RLS with PFO (19,20); however, large
ase series are lacking in the literature. Although pulmonary
ngiography is the gold standard for diagnosing PAVM,
ontrast-enhanced TTE has been shown to have high
ositive predictive value for normal respiration (n  12 of
2) (21). The timing of appearance of contrast microbubbles
n TTE may not be associated with the presence of PAVM
n computed tomography (21,22). Undiagnosed coexisting
SD can also result in residual RLS following PFO closure;
owever, the use of color-flow Doppler interrogation in the
resent study reduced the probability of an incorrect ASD
iagnosis (23).
The results of the present study are limited in their
eneralizability to the larger PFO population. This study
as limited by the small number of patients and the high
umber of patients (21%) lost to follow-up. Swedish Med-
cal Center is a regional referral center, and many of these
atients lived in outlying areas or other states and were
nable to return for follow-up. Nevertheless, post hoc
nalysis showed that this study had adequate statistical
ower (0.97) to test the effect of secondary source of RLS on
ate residual RLS.
The short duration of follow-up (192 days, 95% CI: 161
o 223 days) is of concern; however, the definition of “late
ollow-up” is inconsistent across PFO closure trials. The
IST (Migraine Intervention with STARFlex Technology)
rial (STARFlex, NMT Medical) used 6 months for final
TE follow-up to assess PFO closure (24). In a previous
etrospective analysis (7), 78% of patients showed no sig-
ificant change in degree of RLS between 1 and 6 months,
nd 82% had no significant change in degree of RLS
etween 6 and 12 months following PFO closure. Pulmo-
ary angiography was not performed to verify presence of
AVM. Selection bias may have been a factor in the results
btained, as all patients underwent PFO closure for preven-
ion of recurrent cerebrovascular events. Clinical sequelae
stroke, transient ischemic attack) were not assessed follow-
ng PFO closure, and the study was not sufficiently powered
o detect a difference in the incidence of recurrent stroke in
atients with and without secondary source of RLS. The
urpose of our study was to obtain preliminary findings on
he prevalence of secondary sources of RLS in patients with
FO at the time of transcatheter PFO closure using a
ompliant sizing balloon, ICE, and TCD. We did not,
owever, collect clinical outcomes data as part of this study.
e have previously published findings on the association
etween residual RLS following PFO closure and clinical
equelae. In this retrospective analysis, age at the time of
FO closure was the only significant univariate predictor of
ecurrent stroke (beta  0.076, p  0.03). There were no
ignificant differences in the risk for recurrent stroke with
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567espect to final closure status, sex, history of multiple strokes,
oexisting atrial septal aneurysm, or hypertension (7).
onclusions
he results of this prospective, preliminary study suggest
hat balloon occlusion, ICE, and TCD can be used during
ranscatheter PFO closure to detect secondary sources of
LS such as PAVM. Patients who had secondary RLS were
ore likely to have late residual RLS. Ongoing PFO studies
tilizing these diagnostic modalities (especially TCD) to
etermine closure status need to factor the current findings
n their design. In addition, future research needs to be
onducted to assess the incidence of recurrent clinical
equelae following PFO closure in patients diagnosed with
secondary source of RLS at the time of PFO closure.
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